We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

PTAB Denies Coherus' Challenge To 2 Enbrel Patents

Law360 (March 12, 2018, 7:42 PM EDT) -- The Patent Trial and Appeal Board on Friday shot down Coherus BioSciences’ request to reevaluate two patents owned by Hoffman-LaRoche Inc., which are licensed to Amgen Inc. for its blockbuster immunosuppressant Enbrel.

Coherus had claimed U.S. Patent Nos. 8,163,522 B1 and 8,063,182 B1 were obvious under two pieces of prior art, but the board didn’t find its argument persuasive. The decision was largely bogged down in the science of how to create and manipulate the patented fusion proteins to end up with the arthritis biologic....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.